All filters
Slidesets
Case discussion: Demonstrative cases of social media based HIV and medical non-HIV programs in the community- Guido van den Berk, MD, PhD
Presented at:
European Workshop on Healthy Living with HIV 2017
Slidesets
ADA-formation and its effect on Mab PK | Maria-Jesus Garrido, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Clinical case discussions | Howard Gurney, MBBS, FRACP
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Evaluation of a physiological based pharmacokinetic model to evaluate the influence of covariates on sunitinib exposure
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Optimal design – potential application in oncology drug development and clinical practice | Andrew Hooker, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Assessment of the release of daunorubicin from liposomes after administration of daunoXome® using population pharmacokinetics
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Model-based TDM for oncology drugs | Ron Keizer, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Physiologically based PK model vs. Population PK approach during drug development | Italo Poggesi, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Opening Lecture: Inter- and intravariability in PK | Mark Ratain, MD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanoma
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Clinical case discussions | Nielka van Erp, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
PK and PKPD considerations for dose selection in the development of pembrolizumab | Dinesh de Alwis, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Clinical Case Discussion 1- Dr. T.R. Constant Vergara
Presented at:
Brazilian HIV Clinical Forum 2017
Slidesets
Is Baseline Resistance Testing Needed?- Ricardo Diaz, MD
Presented at:
Brazilian HIV Clinical Forum 2017
Slidesets
Clinical Case Discussion 3- Dr. M.C.Rachid de Lacerda
Presented at:
Brazilian HIV Clinical Forum 2017
Slidesets
The Role of HIV Integrase Inhibitors in PrEP & PEP- Richard Elion
Presented at:
Brazilian HIV Clinical Forum 2017
Slidesets
HIV Integrase Inhibitors in an Aging Population (Polypharmacy - Comorbidities)- Dr. M.C.Rachid de Lacerda
Presented at:
Brazilian HIV Clinical Forum 2017
Slidesets
Clinical Case on Integrase Inhibitors Use in TB-Infected Patients- Dr. L. Grinsztejn
Presented at:
Brazilian HIV Clinical Forum 2017
Meeting
Global HIV Clinical Forum 2017
Slidesets
Basic Science of Integrase Inhibitors - Recent Advances- Francois Clavel, MD
Presented at:
Global HIV Clinical Forum 2017